Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 19 Aug 2021
Miravo Healthcare announces receipt of Health Canada Notice of Compliance for the paediatric use of Blexten
12 August 2021 - Blexten Label Expanded to Include Ages as Young as 4 Years Old. ...
Posted by Michael Wonder on 19 Aug 2021
TGA reduces timeframe for publishing adverse event reports
19 August 2021 - With strong public interest in adverse event reports relating to COVID-19 vaccinations, and improvements in our ...
Posted by Michael Wonder on 18 Aug 2021
NICE publishes final guidance on the use of a topical gel for patients with a rare cancer
18 August 2021 - Chlormethine gel for is used for the treatment of patients with mycosis fungoides type cutaneous T-cell lymphoma. ...
Posted by Michael Wonder on 18 Aug 2021
MS drug: Hull couple's treatment denied by 'cruel' postcode lottery
18 August 2021 - A couple who both have multiple sclerosis say they are being denied a drug which could ...
Posted by Michael Wonder on 18 Aug 2021
WHO calls on Roche to ensure fair access to COVID-19 drug amid shortage
18 August 2021 - The World Health Organization called on Wednesday on Roche to ensure fair distribution of its arthritis ...
Posted by Michael Wonder on 18 Aug 2021
FDA grants breakthrough device designation to Impella ECP, the world’s smallest heart pump
18 August 2021 - The United States FDA has granted breakthrough device designation to Abiomed’s Impella ECP expandable percutaneous heart ...
Posted by Michael Wonder on 18 Aug 2021
ICER releases draft evidence report on mavacamten for hypertrophic cardiomyopathy
18 August 2021 - Public comment period now open until 15 September 2021; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 18 Aug 2021
US FDA approves Jardiance (empagliflozin) to treat adults living with heart failure with reduced ejection fraction
18 August 2021 - New treatment options are critical, as approximately half of all people with heart failure die within five ...
Posted by Michael Wonder on 18 Aug 2021
Talks to recover reimbursement for dementia treatment aid almost complete
18 August 2021 - The negotiations on retrieving the reimbursement of pharmaceutical pricing for choline alfoscerate drugs to help treat ...
Posted by Michael Wonder on 18 Aug 2021
Sutro Biopharma announces STRO-002 FDA fast track designation for patients with advanced ovarian cancer
18 August 2021 - Sutro Biopharma today announced that the U.S. FDA has granted fast track designation for STRO-002, a folate ...
Posted by Michael Wonder on 18 Aug 2021
Joint statement from HHS public health and medical experts on COVID-19 booster shots
18 August 2021 - Today, public health and medical experts from the U.S. Department of Health and Human Services released the ...
Posted by Michael Wonder on 18 Aug 2021
Update on Actemra (tocilizumab) supply in the U.S.
16 August 2021 - The unprecedented surge in worldwide demand and supply constraints driven by Delta variant spikes in much ...
Posted by Michael Wonder on 18 Aug 2021
AmoyDx Pan lung cancer PCR panel receives MHLW approval as companion diagnostic for Tepmetko (tepotinib)
17 August 2021 - Riken Genesis, Amoy Diagnostics and Precision Medicine Asia today announced that the Ministry of Health, Labour ...
Posted by Michael Wonder on 18 Aug 2021
Abiraterone acetate for treating newly diagnosed high-risk hormone sensitive metastatic prostate cancer
18 August 2021 - NICE has published final guidance on the use of Zytiga in newly diagnosed patients following an ...
Posted by Michael Wonder on 18 Aug 2021
COVID-19 vaccines additional doses: codes & payment
16 August 2021 - The FDA amended the emergency use authorisations for both the Pfizer BioNTech COVID-19 vaccine and the ...